Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2001-10-01
2008-08-19
Kosar, Andrew D. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S010100, C514S011400, C514S014800, C530S300000, C530S317000, C530S327000, C530S333000
Reexamination Certificate
active
07414023
ABSTRACT:
The present invention relates to novel peptide ligands for prostate specific antigen (PSA) binding specifically with it and enhancing its enzyme activity, to a process for preparation of these peptides, to diagnostic and pharmaceutical compositions comprising these peptides, to the use of these peptides for pharmaceutical and research preparations, to methods using these peptides in diagnostic assays for determination of the concentrations of various molecular forms of PSA, to methods for modulating the PSA enzyme activity and PSA activity dependent conditions by using these peptides either in vivo or in vitro and to the use of these peptides in procedures for biochemical isolation and purification of PSA.
REFERENCES:
patent: 0905142 (1999-03-01), None
L. Leinonen, et al. Scand. J. Clin. Lab. Invest. (2000) 60(233 Suppl), pp. 59-64.
W.-M. Zhang, et al. Scand. J. Clin. Lab. Invest. (2000) 60(233 Suppl), pp. 51-58.
P. Wu, et al. Eur. J. Biochem. (2000) 267, pp. 6212-6220.
“Motif” On-line Medical Dictionary <<http://www.cancerweb.ncl.c/uk/od/>> 1 page; accessed Nov. 14, 2006.
“Motif” Drug Discovery and Development Glossary <<http://www.ddmag.com/scripts/glossary.asp>>1 page, accessed Nov. 14, 2006.
A.S. Edwards, et al. J. Biol. Chem. (1997) 272(29), pp. 18382-18390.
Ravi P. Nargund, et al., Journal of Medicinal Chemistry vol. 41, No. 17, Aug. 13, 1998, pp. 3103-3127.
Wadih Arap, et al., Cancer Treatment by Target Drug Delivery to Tumor Vasculature in a Mouse Model vol. 279 Jan. 16, 1998.
U.-H. Stenman, et al., Summary Report of the TD-3 Workshop: Characterization of 83 Antibodies against Prostate-Specific Antigen Tumor Biol, 1999 vol. 20, No. 1, pp. 1-12.
M.C. Wang, et al., Purification Of A Human Prostate Specific Antigen, Mar. 26, 1979, pp. 159-163.
Hans Lilja, et al. Seminal Vesicle-Secreted Proteins and Their Reactions during Gelation and liquefaction of Human Semen, vol. 80 Aug. 1987, 281-285.
U.K. Laemmli., Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 Nature, vol. 227, Aug. 15, 1970.
Harry Towbin, et al., Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications, vol. 76, No. 9, Sep. 1979, pp. 4350-4354.
P. Guntert C. Mumenthaler, et al., Torsion Angle Dynamics for NMR Structure Calculation with the New Program Dyana, vol. 76, No. 9, Sep. 1979, pp. 283-298.
Gail Hutchinson, et al., A revised set of potentials for β-turn formation in proteins., vol. 3, Oct. 10, 1994 pp. 2207-2216.
B. H. Meier, et al., Investigation of exchange processes by two-dimensional NMR spectroscopy, vol. 71, No. 11, Dec. 1, 1979 pp. 4546-4553.
Allister J. Maynard, et al., Origin of β-Hairpin Stability in Solution: Structural and Thermodynamic Analysis of the Folding of a Model Peptide Supports Hydrophobic Stabilization in Water, vol. 120, 1998, pp. 1996-2007.
Lars Sottrup-Jensen, α-Macroglobulins: Structure, Shape, and Mechanism of Proteinase Complex Formation, vol. 264, No. 20, Jul. 15, 1989, pp. 11539-11542.
Hannu Koistinen, et al., Different Forms of Insulin-Like Growth Factor-Binding Protein-3 Detected in Serum and Seminal Plasma by Immunofluorometric Assay with Monoclonal Antibodies, vol. 40, No. 4, 1994.
Pinchas Cohen, et al., Prostate-Specific Antigen (PSA) is an Insulin-Like Growth Factor Binding Protein-3 Protease Found in Seminal Plasma, vol. 75, No. 4. 1992, pp. 1046-1053.
Janita Lovegren1, et al., Production of Recombinant PSA And HK2 And Analysis Of Their Immunologic Cross-Reactivity, vol. 213, No. 3, Aug. 24, 1995, pp. 888-895.
Erkki Koivunen, et al., Human Ovarian Tumor-associated Trypsin, vol. 264, No. 24, Aug. 25, 1989, pp. 14095-14099.
Erkki Koivunen, et al., [17] Peptides in Cell Adhesion Research, 1994, pp. 347-369.
Daniel Rajotte, et al., Molecular Heterogeneity of the Vascular Endotherlium Revealed by in Vivo Phage Display, vol. 102, No. 2, Jul. 1998, pp. 430-437.
Vladimir A.Slepushkin, et al., Targeting of Liposomes to HIV-1-Infected Cells by Peptides Derived from the DC4 Receptor, vol. 227, 827-833 (1996), Article No. 1592.
Samuel Zalipsky, et al. Peptide Attachments to Extremities of Liposomal Surface Grafted PEG Chains: Preparation of the Long-Circulating Form of Laminin Pentapeptide, YIGSR, vol. 6, 1995, pp. 705-708.
Richard P. Harbottle, et al., An RGD-Oligolysine Peptide: A Prototype Construct for Integrin-Mediated Gene Delivery, vol. 9, May 1, 1998, pp. 1037-1047.
Richard A. Houghten, et al., Journal of Medicinal Chemistry, vol. 42, No. 19, Sep. 23, 1999 pp. 3743-3778.
Robert J. Fisher, et al., Surface plasmon resonance based methods for measuring the kinetics and binding affinities of biomolecular interactions, pp. 389-395.
Zuxiong Chen, et al., Prostate Specific Antigen In Benign Prostatic Hyperplasia: Purification and Characterization, vol. 157, Jun. 1997, pp. 2166-2170.
Stephen D. Mikolajczyk, et al., A Precursor Form of PSA (pPSA) Is A Component Of The Free PSA In Prostate Cancer Serum, vol. 50, 1997, pp. 710-714.
Ulf-H{dot over (a)}kan Stenman, et al., A Complex between Prostate-specific Antigen and α1-Antichymotrypsin Is the Major Form of Prostate-specific Antigen in Serum of Patients with Prostatic Cancer: Assay of the Complex Improves Clinical Sensitivity for Cancer1, vol. 51, Jan. 1, 1991, pp. 222-226.
Wan-Ming Zhang, et al., Purification and Characterization of Different Molecular Forms of Prostate-Specific Antigen in Human Seminal Fluid, vol. 41, No. 11, Jun. 27, 1995, pp. 1567-1573.
Sirkka-Liisa Karonen, et al., Localization of Human Malignant Tumors with Radioiodinatd Recombinant Tissue Plasminogen Activator, vol. 29, Jan. 27, 1988, pp. 1194-1199.
Ilkka Hemmilä, et al., Europium as a Label in Time-Resolved Immunofluorometric Assays, vol. 137, 1984, pp. 335-343.
Gary S. Coombs1, et al., Substrate specificity of prostate-specific antigen (PSA), vol. 5, Sep. 1998, pp. 475-488.
Hans Lilja, et al., Semenogelin, the Predominant Protein in Human Semen, vol. 264, No. 3, Jan. 25, 1989, pp. 1894-1900.
Jamie K. Scott, et al., Searching for Peptide Ligands with an Epitope Library, vol. 249, Jun. 13, 1990, pp. 386-390.
Sibo Feng, et al., Specific interactions outside the proline-rich core of two classes of Src homology 3 ligands, vol. 92, Dec. 1995, pp. 12408-12415.
Bradley A. Katz, et al., Design of potent selective zinc-mediated serine protease inhibitors, vol. 391, Feb. 5, 1998, pp. 608-612.
Jeremy M. Berg, et al., The Galvanization of Biology: A Growing Appreciation for the Roles of Zinc, vol. 271, Feb. 23, 1996, pp. 1081-1085.
Wan-Ming Zhang, et al., Characterization and immunological determination of the complex between prostate-specific antigen and α2-macroglobulin, vol. 44, No. 12, Sep. 28, 1998, pp. 2471-2479.
Hans Lilja, et al., Seminal Vesicle-secreted Proteins and Their Reactions during Gelation and Liquefaction of Human Semen, vol. 80, Aug. 1987, pp. 281-285.
M.C. Wang, et al., Purification of a Human Prostate Specific Antigen1, pp. 159-163.
U.-H. Stenman, et al., Summary Report of the TD-3 Workshop: Characterization of 83 Antibodies against Prostate-Specific Antigen, vol. 20, No. 1, 1999, pp. 1-12.
Wadih Arap, et al. Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model, vol. 279, Jan. 16, 1998,.pp. 377-380.
Ravi P. Nargund, et al., Journal of Medicinal Chemistry, vol. 41, No. 17, Aug. 13, 1998, pp. 3104-3127.
Samuel R. Denmeade, et al., Enzymatic Activation of a Doxorubicin-Peptide Prodrug by Prostate-Specific Antigen1, Vol. 58, Jun. 15, 1998, pp. 2537-2540.
Samuel R. Denmeade, et al., Specific and Efficient Peptide Substrates for Assaying the Proteolytic Activity of Prostate-specific Antigen1, vol. 57, Nov. 1, 1997, pp. 4924-4930.
Geoffrey M. Gersuk, et al., High-Affinity Peptide Ligands to Prostate-Specific Antigen Identified by Polysome Selection, vol. 232, 1997, pp. 578-582.
Gregory P. Adams, et al., Generating improved single-chain Fv molecules for tumor targeting, vol. 231, 1999, pp. 249-260.
H-H Heidtmann, et al., Generat
Koivunen Erkki
Leinonen Jari
Närvänen Ale
Ulf-Hakan Stenman
Kosar Andrew D.
Licentia Ltd.
Sughrue & Mion, PLLC
LandOfFree
Peptide ligands for prostate specific antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide ligands for prostate specific antigen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide ligands for prostate specific antigen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4014956